LT3515924T - Kristalinės formos - Google Patents

Kristalinės formos

Info

Publication number
LT3515924T
LT3515924T LTEPPCT/EP2017/073858T LT17073858T LT3515924T LT 3515924 T LT3515924 T LT 3515924T LT 17073858 T LT17073858 T LT 17073858T LT 3515924 T LT3515924 T LT 3515924T
Authority
LT
Lithuania
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
LTEPPCT/EP2017/073858T
Other languages
English (en)
Lithuanian (lt)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of LT3515924T publication Critical patent/LT3515924T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEPPCT/EP2017/073858T 2016-09-22 2017-09-21 Kristalinės formos LT3515924T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
LT3515924T true LT3515924T (lt) 2022-03-10

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/073858T LT3515924T (lt) 2016-09-22 2017-09-21 Kristalinės formos

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3981774A1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
DK4181872T3 (da) 2020-07-15 2026-01-26 Viatris Asia Pacific Pte Ltd Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist
MX2024000653A (es) * 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CA2507657C (en) 2002-12-11 2011-05-31 Bayer Schering Pharma Aktiengesellschaft 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
PT1611144E (pt) 2003-04-09 2010-11-12 Wyeth Llc Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
WO2010116328A2 (en) 2009-04-08 2010-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
KR101728180B1 (ko) 2009-04-22 2017-04-18 액테리온 파마슈티칼 리미티드 티아졸 유도체들 및 p2y12 수용체 길항제로서 이들의 용도
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
DK4181872T3 (da) 2020-07-15 2026-01-26 Viatris Asia Pacific Pte Ltd Vandig, farmaceutisk sammensætning omfattende en p2y12 receptorantagonist

Also Published As

Publication number Publication date
US20210009614A1 (en) 2021-01-14
JP7097369B2 (ja) 2022-07-07
US20250163086A1 (en) 2025-05-22
UA124073C2 (uk) 2021-07-14
IL265445B2 (en) 2024-05-01
JP2019529553A (ja) 2019-10-17
PH12019500567A1 (en) 2019-11-18
IL265445B1 (en) 2024-01-01
TWI752086B (zh) 2022-01-11
US20220275011A1 (en) 2022-09-01
MA46266B1 (fr) 2022-02-28
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
US10730896B2 (en) 2020-08-04
RS62946B1 (sr) 2022-03-31
CN109715639A (zh) 2019-05-03
KR102552795B1 (ko) 2023-07-06
CA3037794A1 (en) 2018-03-29
SI3515924T1 (sl) 2022-04-29
PH12019500567B1 (en) 2024-01-31
US20200017534A1 (en) 2020-01-16
EP3981774A1 (en) 2022-04-13
US11365209B2 (en) 2022-06-21
MX2019003093A (es) 2019-07-18
WO2018055016A1 (en) 2018-03-29
US12227532B2 (en) 2025-02-18
MX381590B (es) 2025-03-12
AU2017331930B2 (en) 2021-07-15
EA201990723A1 (ru) 2019-10-31
TW201813965A (zh) 2018-04-16
HUE057772T2 (hu) 2022-06-28
EP3515924A1 (en) 2019-07-31
MY193080A (en) 2022-09-26
BR112019004845A2 (pt) 2019-06-04
HRP20220234T1 (hr) 2022-05-13
EP3515924B1 (en) 2021-12-15
IL265445A (en) 2019-05-30
CN109715639B (zh) 2022-04-19
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
PT3515924T (pt) 2022-03-11
ES2908572T3 (es) 2022-05-03
KR20190052704A (ko) 2019-05-16
CL2019000728A1 (es) 2019-07-05
AU2017331930A1 (en) 2019-03-07
CY1125052T1 (el) 2024-02-16

Similar Documents

Publication Publication Date Title
FIC20240013I1 (fi) Lebrikitsumabi
DK3405050T3 (da) Børnesikret snusbeholder
EP3362225C0 (en) PULSE TOOL
DK3392584T3 (da) Nukleation
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
EP3551650A4 (en) IL-1RA ADNC
EP3227309C0 (en) CRYSTALLINE DIFUCOSYLLACTOSE
EP3538520C0 (en) CGS STIMULATORS
LT3519394T (lt) Kalkobutrolio modifikacijos kristalinės formos gavimo būdas
DK3452590T3 (da) Plademagnet
LT3597189T (lt) Kristaliniai junginia
EP3476198A4 (en) HARVESTER
DK3819287T3 (da) Amorft tapentadolphosphat
EP3454846A4 (en) CRYSTALS
DK3463553T3 (da) Unipolar kanyle
DE112017000734A5 (de) Glycolsensor
PL3400217T3 (pl) L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna
DK3244717T3 (da) Jordbearbejdningsredskab
PL3630725T3 (pl) Postać krystaliczna n-butylodeoksygalaktonojirymycyny
MA46266A (fr) Formes cristallines
DE112017006386A5 (de) Schraubarbeitszylinder
DK3323708T3 (da) Bovfender